

STATE OF NEW YORK

10521--A

IN ASSEMBLY

March 6, 2026

Introduced by M. of A. HEVESI -- read once and referred to the Committee on Health -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

AN ACT to amend the public health law, in relation to newborn screening for CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

1 Section 1. Subdivision 1 of section 2500-a of the public health law is
2 amended by adding five new paragraphs (l), (m), (n), (o) and (p) to read
3 as follows:

4 (l) Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2).

5 (m) Mucopolysaccharidosis type IVA (MPS IVA).

6 (n) Mucopolysaccharidosis type VI (MPS VI).

7 (o) Mucopolysaccharidosis type VII (MPS VII).

8 (p) Fabry.

9 § 2. Section 2500-a of the public health law is amended by adding a
10 new subdivision 4 to read as follows:

11 4. The commissioner shall ensure tests are made available for all
12 diseases and conditions designated pursuant to paragraphs (l), (m), (n),
13 (o) and (p) of subdivision one of this section within twelve months of
14 the effective date of such paragraphs.

15 § 3. This act shall take effect immediately.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[-] is old law to be omitted.

LBD15047-02-6